Diana Heaugwane

Ms. Diana Heaugwane

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2021 in Cancers
Verified
Journal Article
Open access
PDF file
GBGuillaume Belthier
Guillaume Belthier
ZHZeinab Homayed
Zeinab Homayed
FGFanny Grillet
Fanny Grillet
CDChristophe Duperray
Christophe Duperray
JVJulie A. Vendrell
Julie A. Vendrell
JPJulie Pannequin
Julie Pannequin
Circulating tumor cells (CTCs) are promising diagnostic and prognostic tools for clinical use. In several cancers, including colorectal and breast, the CTC load has been associated with a therapeutic response as well as progression-free and overall survival. However, counting and isolating CTCs remains sub-optimal because they are currently largely identified by epithelial markers such as EpCAM. New, complementary CTC surface markers are therefore urgently needed. We previously demonstrated that a splice variant of CD44, CD44 variable alternative exon 6 (CD44v6), is highly and specifically expressed by CTC cell lines derived from blood samples in colorectal cancer (CRC) patients. Two different approaches—immune detection coupled with magnetic beads and fluorescence-activated cell sorting—were optimized to purify CTCs from patient blood samples based on high expressions of CD44v6. We revealed the potential of the CD44v6 as a complementary marker to EpCAM to detect and purify CTCs in colorectal cancer blood samples. Furthermore, this marker is not restricted to colorectal cancer since CD44v6 is also expressed on CTCs from breast cancer patients. Overall, these results strongly suggest that CD44v6 could be useful to enumerate and purify CTCs from cancers of different origins, paving the way to more efficacious combined markers that encompass CTC heterogeneity.

14 December 2022 in Langmuir
Verified
Journal Article
Closed access
KBKedafi Belkhir
Kedafi Belkhir
OCOrélia Cerlati
Orélia Cerlati
DHDiana Heaugwane
Diana Heaugwane
ATAlice Tosi
Alice Tosi
BBBelkacem Tarek Benkhaled
Belkacem Tarek Benkhaled
VLVincent Lapinte
Vincent Lapinte

1 May 2024 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
DHDiana Heaugwane
Diana Heaugwane
OCOrélia Cerlati
Orélia Cerlati
Kedafi BelkhirKedafi Belkhir
Kedafi Belkhir
BBBelkacem Tarek Benkhaled
Belkacem Tarek Benkhaled
SCSylvain Catrouillet
Sylvain Catrouillet
LGLaure Gibot
Laure Gibot
Because of the difficult challenges of nanopharmaceutics, the development of a variety of nanovectors is still highly desired. Photodynamic therapy, which uses a photosensitizer to locally produce reactive oxygen species to kill the undesired cells, is a typical example for which encapsulation has been shown to be beneficial. The present work describes the use of coumarin-functionalized polymeric nanovectors based on the self-assembly of amphiphilic poly(2-oxazoline)s. Encapsulation of pheophorbide a, a known PDT photosensitizer, is shown to lead to an increased efficiency compared to the un-encapsulated version. Interestingly, the presence of coumarin both enhances the desired photocytotoxicity and enables the crosslinking of the vectors. Various nanovectors are examined, differing by their size, shape and hydrophilicity. Their behaviour in PDT protocols on HCT-116 cells monolayers is described, the influence of their crosslinking commented. Furthermore, the formation of a protein corona is assessed.